Coldstream Laboratories announces manager of technology transfer

Sholto Maclean takes newly created role at Kentucky firm

Coldstream Laboratories, a US provider of drug product research and manufacturing services specialising in high potency and cytotoxic parenteral products, based in Lexington, Kentucky, has named Sholto Maclean as manager of technology transfer.

In this newly created position, Maclean will work with Coldstream's pharmaceutical development team to scale up processes for sterile liquid and lyophilised drug products for manufacturing in the company's sterile facility.

Maclean has more than 20 years of experience in parenteral processing, sterile product development, lyophilisation development and aseptic manufacturing. Most recently, he was a lyophilisation/technology transfer consultant for a major pharmaceutical company. Previous roles include positions at GlaxoSmithKline and DSM Pharmaceuticals.

Coldstream Laboratories operates the only sterile pharmaceutical manufacturing facility in Kentucky.

You may also like

Manufacturing

Piramal acquires Coldstream Laboratories for US$30.65m

Kentucky based CDMO specialises in sterile liquid and freeze-dried parenterals and injectables
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now